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Abstract 
Objective: The human Rho guanine nucleotide exchange factor 11 (ARHGEF11) gene is 
one of the candidate genes for type 2 diabetes mellitus (T2DM).  ARHGEF11 is mapped to 
chromosome 1q21, which has susceptible risk loci for T2DM and schizophrenia.  We 
hypothesized that ARHGEF11 contributes to the pathogenesis of schizophrenia. 
Method: We selected eight single nucleotide polymorphisms of ARHGEF11 that had 
significant associations with T2DM for a case-control association study of 490 patients with 
schizophrenia and 500 age- and sex- matched controls. 
Results: We did not find any differences in allelic, genotypic associations, or minor 
allele frequencies with schizophrenia.  Analysis of the rs6427340-rs6427339 haplotype 
and the rs822585-rs6427340-rs6427339 haplotype combination provided significant evidence 
of an association with schizophrenia (global permutations P=0.00047 and 0.0032, 
respectively).  C-C of the rs6427340-rs6427339 haplotype and A-C-C of the 
rs822585-rs6427340-rs6427339 haplotype carried higher risk factors for schizophrenia 
(permutation P=0.0010 and 0.0018, respectively).  A-C-T of the 
rs822585-rs6427340-rs6427339 haplotype had a possible protective effect (permutation 
P=0.031). 
 Conclusion: These results provide new evidence that ARHGEF11 may constitute a risk 
factor for schizophrenia. 
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1. Introduction 
 
It is well established that patients with schizophrenia are at increased risk for the 
development of type 2 diabetes mellitus (T2DM) (Bushe and Holt, 2004; Suvisaari et al., 
2008).  Epidemiological surveys show that the prevalence of T2DM in patients with 
schizophrenia is approximately 6% to 21%, two to three times higher than in the general 
population (Bushe and Holt, 2004; Suvisaari et al., 2008).  Some studies have suggested that 
the medication used to treat schizophrenia may contribute to the risk of diabetes (Scheen and 
De Hert, 2007; Tschoner et al., 2007).  However, apart from adverse effects related to 
medication, recent studies show an elevated risk of T2DM among drug-naïve or first-episode 
patients with schizophrenia and their relatives (Ryan et al., 2003, Spelman et al., 2007; Guest 
et al., 2010).  Thus, T2DM and schizophrenia are common diseases that seem to share a 
complex mode of inheritance that includes both genetic factors and environmental 
determinants (Gough and O’Donovan, 2005). 
Previous genetic studies show that T2DM and schizophrenia have a number of 
overlapping risk loci, including chromosomes 1p13, 1p36, 1q21-24, 1q25, 2q14, 2q33, 2q36, 
3p22, 3q29, 4q25, 5q13, 6p21, 6q25, 7p15, 7p21, 7q21, 7q31, and 9p24 (Lin and Shuldiner, 
2010).  Chromosome 1q21 was reported to have a linkage to T2DM by several previous 
studies (Vionnet et al., 2000; Das and Elbein, 2007).  This location has also been implicated 
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as a schizophrenia susceptibility locus (Brzustowicz et al., 2000; Craddock et al., 2005).  
The human Rho guanine nucleotide exchange factor 11 (ARHGEF11) gene is located in 
chromosome 1q21, and ARHGEF11 variants have been associated with T2DM in multiple 
ethnic populations (Fu et al., 2007; Ma et al., 2007; Böttcher et al., 2008; Jin et al., 2010; Liu 
et al., 2011).   
ARHGEF11 is expressed in the pancreas, liver, adipose tissue (Fukuhara et al., 1999), 
and multiple brain regions (Huerta et al., 2006).  It mediates interaction with the actin 
cytoskeleton (Banerjee and Wedegaertner; 2004) and activates RhoA GTPases that belong to 
small GTP-binding proteins of Rho families (Fukuhara et al., 1999; Rümenapp et al., 1999).  
Rho GTPases play fundamental roles in the regulation of G protein signaling and a number of 
cellular processes, including insulin secretion (Hirosumi et al., 2002), insulin signaling 
(Kowluru and Veluthakal, 2005), and lipid metabolism (Houssa et al., 1999).  Rho GTPases 
are also implicated in the regulation of neuronal morphogenesis, including migration, polarity, 
axon growth, axon guidance, dendrite elaboration, dendrite plasticity, and synapse formation 
(Luo, 2000). 
In a yeast two-hybrid screen, ARHGEF11 directly interacted with 
disrupted-in-schizophrenia 1 (DISC1), which is one of the candidate genes for schizophrenia 
(Millar et al., 2003).  DISC1 modulates the structure and function of the spines of the 
glutamate synapse via another member of the RhoGEF family, KALRN (Hayashi-Takagi et 
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al., 2010). 
We hypothesized that ARHGEF11 contributes to the pathogenesis of schizophrenia.  
Therefore, we examined the association between patients with schizophrenia and ARHGEF11. 
 
2. Methods 
 
2.1. Subjects 
 
The subjects of this association study comprised 490 unrelated patients fulfilling the 
ICD-10 (International Classification of Disease, Version 10, WHO 1992) diagnostic criteria 
for schizophrenia (250 males and 240 females, average age ± standard deviation (S.D.), 50.5 
± 12.8 years; 223 were diagnosed with the paranoid subtype, 241 with the hebephrenic 
subtype, 18 with the catatonic subtype, and 8 with the undifferentiated subtype), and 500 age-, 
sex-, and geographical origin-matched control subjects (250 males and 250 females, average 
age ± S.D., 51.0 ± 14.5 years).  Diagnosis of schizophrenia and determination of subtype 
were performed by two trained psychiatrists on the basis of all available information and 
unstructured interviews.  We excluded the catatonic subtype due to the low sample size and 
the undifferentiated subtype due to its heterogeneity.  Controls were recruited primarily from 
medical staff members.  Psychiatrically, medically, and neurologically healthy controls were 
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evaluated using unstructured interviews to exclude individuals who had current or past 
contact with psychiatric services.  All subjects were Japanese.  This study was approved by 
the Ethics Committee of Okayama University Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences.  Written informed consent was obtained from all participants. 
 
2.2. Genotyping 
 
Peripheral blood was obtained from the subjects, and genomic DNA was extracted from 
peripheral leukocytes using a standard procedure.  We selected eight single nucleotide 
polymorphisms (SNPs), rs822585, rs6427340, rs6427339, rs1006168, rs12136088, rs2275199 
(N1207N), rs868188 (S1456G), and rs945508 (R1467H), of ARHGEF11 for genetic 
association analyses (see Fig. 1).  These eight SNPs have shown significant associations 
with T2DM (Fu et al., 2007; Ma et al., 2007; Böttcher et al., 2008; Jin et al., 2010; Liu et al., 
2011).  The concentration and purity of DNA samples was assessed using a NanoDrop 1000 
spectrophotometer (Thermo Scientific, USA).  The concentration of DNA samples was 
adjusted to 20 ng/μl.  The purity was estimated from the ratio of the absorbance values 
measured at wavelengths of 260 nm and 280 nm (defined as a 260/280 ratio between 1.8 and 
2.0).  Eight SNPs (rs822585, rs6427340, rs6427339, rs1006168, rs12136088, rs2275199, 
rs868188, and rs945508) were genotyped with a TaqMan assay (Assay ID:  
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C___1818078_10, C___1818022_20, C___1818021_20, C___1818013_10, 
C__31432570_10, C__16183901_10, C___1468852_10, and C___1468853_10, respectively, 
Applied Biosystems, USA) with a Real Time QPCR System Mx3000P (Agilent Technologies, 
USA).  PCR reaction was carried out on 16 μl of a solution containing approximately 0.2 μl 
TE buffer, 0.2 μl ready-to-use PCR probe, 2 μl genomic DNA, 8 μl Brilliant II FAST QPCR 
Master Mix (Agilent Technologies), and 5.6 μl DNase-free water.  PCR cycling conditions 
consisted of an initial incubation at 95°C for 2 min, followed by 40 cycles of 92°C for 30 sec 
and 60°C for 1 min, for the annealing/elongation steps.  An experienced researcher 
conducted the genotyping and read out the data, and the genetic variants were verified by 
repeat PCR. 
 
2.3. Statistical analyses 
 
Statistical analyses were performed using Statcel software for Windows version 2.0 (OMS 
Ltd., Japan).  Associations between categorical variables were analyzed using χ2 test and 
continuous variables were analyzed using Mann-Whitney’s U test.  Deviation from 
Hardy-Weinberg equilibrium and case-control association were examined by χ2 test.  SNPs 
with Hardy-Weinberg equilibrium below 0.05 in either patients or controls were excluded 
from further analyses.  We evaluated pairwise linkage disequilibrium (LD) among the SNPs 
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by χ2 test, and D’ and r2 values.  In haplotype analyses, we calculated the permutation P 
value by using 100,000 simulations to avoid the possibility that a large error could occur in 
the χ2 test when the haplotype frequency was extremely small.  To avoid misleading global 
haplotype results caused by rare haplotypes, we limited haplotypes to those having 
frequencies of at least 1% in either patients or controls.  These statistical analyses were 
performed by using the software SNPAlyze (version 4.2; Dynacom Co., Japan).  The 
statistical significance was set at P <0.05.  Comparisons between schizophrenia patients 
of paranoid and hebephrenic subtypes and normal controls reveal P values 
<0.05/3=0.016.  Furthermore, we performed a post hoc power calculation using a G* power 
program (Faul et al., 2007).  We found that the sample size had >0.90 power for detecting a 
significant association (alpha level <0.05) when an effect size index of 0.2 was used. 
 
2.4. In silico analysis of SNP functions 
 
To investigate the functions of non-synonymous SNPs of ARHGEF11, we used the in 
silico analysis program Polyphen on the SNPinfo Web Server 
(http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm). 
 
3. Results 
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 3.1. Genetic association analyses 
 
The genotype and allele frequencies for each SNP of patients with schizophrenia and 
controls are shown in Table 1.  The eight SNPs did not deviate from Hardy-Weinberg 
equilibrium.  Therefore, we performed the following analyses.  We did not find significant 
differences in genotype, allele frequencies, or minor allele frequencies between patients 
with schizophrenia and controls.  After stratification by subtype of schizophrenia, we 
did not find significant differences in genotype, allele frequencies, or minor allele carrier 
frequencies. 
 
3.2. Haplotype association analyses 
 
Table 2 shows the pairwise LD among eight SNPs of ARHGEF11 using D’ and r2 values 
as an index.  According to these results, we found two LD blocks, block 1 containing 
rs822585, rs6427340, and rs6427339 (D’ ranging between 0.93 and 0.98, and r2 ranging 
between 0.85 and 0.92), and block 2 containing rs1006168 and rs12136088 (D’ of 0.98, and r2 
of 0.97).  We then analyzed two- and three-loci haplotypes in block 1, and two-loci 
haplotypes in block 2 of patients with schizophrenia and controls.  We found significant 
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differences in the frequencies of rs6427340-rs6427339 and rs822585-rs6427340-rs6427339 
haplotypes of ARHGEF11 in block 1 (global permutation P=0.00047 and 0.0032, 
respectively).  The frequencies of C-C of rs6427340-rs6427339 and A-C-C of 
rs822585-rs6427340-rs6427339 in schizophrenia were higher (permutation P=0.0010 and 
0.0018, respectively) than in controls, indicating a higher risk for schizophrenia.  The 
frequencies of A-C-T of rs822585-rs6427340-rs6427339 in schizophrenia were lower 
(permutation P=0.031) than in controls, indicating a possible protective effect (see Table 3). 
After stratification by subtype of schizophrenia, we found significant differences in the 
frequencies of the rs6427340-rs6427339 and rs822585-rs6427340-rs6427339 haplotypes 
between the paranoid subtype and controls (global permutation P=0.0018 and 0.0077, 
respectively) and between the hebephrenic subtype and controls (global permutation 
P=0.00007 and 0.00025, respectively).  The frequencies of C-C of rs6427340-rs6427339 and 
A-C-C of rs822585-rs6427340-rs6427339 in the hebephrenic subtype (permutation 
P=0.00005 and 0.000083, respectively) were higher than in controls, indicating a higher risk 
for schizophrenia.  The frequency of C-T of rs6427340-rs6427339 in the paranoid subtype 
(permutation P=0.016) was lower than in controls, indicating a possible protective effect (see 
Table 3). 
 
3.3. In silico analysis of SNP functions 
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 Rs868188 (S1456G) had a predicted sequence conservation score of 0.012 and was 
predicted to be “benign”.  Rs945508 (R1467H) had a predicted sequence conservation score 
of 0.168 and was predicted to be “possibly damaging”.   
 
4. Discussion 
 
To the best of our knowledge, this is the first genetic association study of ARHGEF11 in 
patients with schizophrenia.  Though we did not find allelic and genotypic associations with 
schizophrenia, analysis of the haplotype combinations provided significant evidence for an 
association with schizophrenia.  It was reported that having the A allele of rs822585, C allele 
of rs6427340, or T allele of rs6427339 was associated with T2DM in an Amish population 
(Fu et al., 2007).  In our study, the frequency of A-C-T of 
rs822585-rs6427340-rs6427339 was significantly higher in controls than in patients with 
schizophrenia.  This result contradicts the view that liability to T2DM is associated 
with vulnerability to schizophrenia.  In the dbSNP database of the NCBI Web Server 
(http://www.ncbi.nlm.nih.gov/projects/SNP), the T allele of rs822585, T allele of 
rs6427340, and C allele of rs6427339 were estimated to be minor alleles in a Japanese 
population (each allele frequency was 20%, 24%, and 24%, respectively).  This data is 
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consistent with our results, and different from that reported for an Amish population.  
A possible explanation for this incongruity may be the difference in ethnic backgrounds.  
In several other individual haplotypes, the frequencies of C-C of rs6427340-rs6427339 
and A-C-C of rs822585-rs6427340-rs6427339 were associated with higher risks for 
schizophrenia.  These haplotypes were also strongly associated with the hebephrenic 
subtype after stratification by subtype of schizophrenia.  However, these differences 
may be mainly due to the low frequencies of rare haplotypes in the controls (haplotype 
frequency was 0.004). 
Minor A allele carriers (GA + AA genotype) of rs945508 (R1467H) were reported to 
have markedly higher risk of T2DM, higher body mass index, higher serum fasting plasma 
glucose, higher fasting insulin, and higher homeostasis model assessment of insulin resistance 
values (Liu et al., 2011).  G allele carriers (GA＋GG genotype) of rs868188 (S1456G) were 
reported to have a higher incidence of T2DM (Ma et al., 2007).  Rs868188 (S1456G) and 
rs945508 (R1467H) are non-synonymous SNPs that result in an amino acid substitution.  In 
silico analysis predicted rs868188 (S1456G) to be “benign”, most likely having no phenotypic 
effect.  Rs945508 (R1467H) was predicted to be “possibly damaging”, in that it may affect 
the protein function and/or structure of ARHGEF11.  Although we did not find significant 
allelic or genotypic associations or minor allele carrier frequencies, the allele frequencies 
of rs822585, rs6427340, rs6427339, and rs868188 (S1456G) (P=0.031, 0.036, 0.023, and 
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0.020, respectively) and minor allele carrier frequencies of rs945508 (R1467H) (P=0.046) 
of ARHGEF11 showed marginally significant associations (P<0.05) between the 
paranoid subtype of schizophrenia and controls.  Because our sample size was small 
after stratification by subtype of schizophrenia, we may need to confirm whether these 
results are only marginal or not using a larger sample.     
It is reported that the expression levels of ARHGEF11 mRNA were higher in the 
postmortem thalamus of patients with schizophrenia than of controls (Davidkova et al., 2003).  
Although the function of ARHGEF11 mRNA overexpressed in the thalamus is unclear, the 
thalamus provides a nodal link for multiple functional circuits, and schizophrenia-associated 
abnormalities in thalamic expression of genes could reflect aberrations in extrathalamic 
components of these circuits (Byne et al., 2009).  Furthermore, it is reported that 
abnormalities in the thalamus may relate to hallucinations in patients with schizophrenia 
(Martínez-Granados et al., 2008).  ARHGEF11 may be associated with the function of the 
thalamus and related to positive symptoms in patients with schizophrenia. 
Several points should be considered in the present study.  The first is that the 
selection of the eight SNPs not based on a Tagger selection program such as Haploview.  
Therefore, further analysis of the remaning SNPs is needed to confirm that ARHGEF11 is 
associated with schizophrenia.  The second is that we subcategorized the subjects with 
schizophrenia according to ICD-10 criteria because the schizophrenia subtypes appear to be 
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more homogeneous than the broader disorder (Mirnics and Lewis, 2001).  However, the 
subtype categories of schizophrenia were eliminated from the Diagnostic and Statistical 
Manual of Mental Disorders-5 due to their limited diagnostic stability, low reliability, and 
poor validity.  Therefore, it might be useless to dichotomize the paranoid and hebephrenic 
subtypes.  The third is that we considered P values <0.05 or 0.016 as statistically 
significant, and therefore found significant associations.  The P value for a significance 
threshold may be 0.0062 (0.05/8) or 0.0020 (0.05/8X3) instead of 0.05 or 0.016 if multiple 
allelic frequencies and genotypic distribution (8SNPs) are considered.  Although 
significant differences might be eliminated after correction for multiple testing, we found 
significant associations with schizophrenia in several haplotype combinations. 
In conclusion, these findings indicated that ARHGEF11 may affect the susceptibility to 
schizophrenia in a Japanese population.  Further replication studies in distinct populations 
and larger sample are necessary to confirm the association between ARHGEF11 and 
schizophrenia. 
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Table 1. 
Genotype and allele frequencies of eight single nucleotide polymorphisms of  ARHGEF11   in controls and patients with schizophrenia.
Location n Genotype P  value Minor allele carrier P  value P  value
rs822585 5' flanking A/A (%) A/T (%) T/T (%) A/T+T/T (%) A (%) T (%)
Control 488 318 (65.2) 143 (29.3) 27 (5.5) 170 (34.8) 779 (79.8) 197 (20.2)
Schizophrenia 462 280 (60.6) 153 (33.1) 29 (6.3) 0.34 182 (39.4) 0.15 713 (77.2) 211 (22.8) 0.15
   Paranoid subtype 209 118 (56.4) 76 (36.4) 15 (7.2) 0.093 91 (43.6) 0.030 312 (74.6) 106 (25.4) 0.031
   Hebephrenic subtype 228 145 (63.6) 70 (30.7) 13 (5.7) 0.91 83 (36.4) 0.68 360 (78.9) 96 (21.1) 0.70
rs6427340 Intron 2 C/C (%) C/T (%) T/T (%) C/T+T/T (%) C (%) T (%)
Control 490 323 (65.9) 141 (28.8) 26 (5.3) 167 (34.1) 787 (80.3) 193 (19.7)
Schizophrenia 475 298 (62.7) 149 (31.4) 28 (5.9) 0.58 177 (37.3) 0.30 745 (78.4) 205 (21.6) 0.30
   Paranoid subtype 215 124 (57.8) 76 (35.3) 15 (6.9) 0.10 91 (42.2) 0.036 324 (75.3) 106 (24.7) 0.036
   Hebephrenic subtype 234 154 (65.8) 67 (28.6) 13 (5.6) 0.99 80 (34.2) 0.98 375 (80.1) 93 (19.9) 0.93
rs6427339 Intron 2 T/T (%) T/C (%) C/C (%) T/C+C/C (%) T (%) C (%)
Control 489 319 (65.2) 143 (29.3) 27 (5.5) 170 (34.8) 781 (79.9) 197 (20.1)
Schizophrenia 475 296 (62.3) 139 (29.3) 40 (8.4) 0.19 179 (37.7) 0.35 731 (76.9) 219 (23.1) 0.12
   Paranoid subtype 213 122 (57.3) 73 (34.3) 18 (8.4) 0.095 91 (42.7) 0.045 317 (74.4) 109 (25.6) 0.023
   Hebephrenic subtype 235 153 (65.1) 60 (25.5) 22 (9.4) 0.12 82 (34.9) 0.97 366 (77.9) 104 (22.1) 0.38
rs1006168 Intron 6 A/A (%) A/C (%) C/C (%) A/C+C/C (%) A (%) C (%)
Control 493 194 (39.4) 232 (47.0) 67 (13.6) 299 (60.6) 620 (62.9) 366 (37.1)
Schizophrenia 467 186 (39.8) 218 (46.7) 63 (13.5) 0.98 281 (60.2) 0.88 590 (63.2) 344 (36.8) 0.89
   Paranoid subtype 212 78 (36.8) 104 (49.1) 30 (14.1) 0.81 134 (63.2) 0.52 260 (61.3) 164 (38.7) 0.57
   Hebephrenic subtype 229 97 (42.4) 102 (44.5) 30 (13.1) 0.74 132 (57.6) 0.44 296 (64.6) 162 (35.4) 0.52
rs12136088 Intron 8 T/T (%) T/G (%) G/G (%) T/G+G/G (%) T (%) G (%)
Control 494 194 (39.3) 231 (46.8) 69 (13.9) 300 (60.7) 619 (62.7) 369 (37.3)
Schizophrenia 474 192 (40.5) 221 (46.6) 61 (12.9) 0.85 282 (59.5) 0.69 605 (63.8) 343 (36.2) 0.59
   Paranoid subtype 215 81 (37.7) 104 (48.4) 30 (13.9) 0.91 134 (62.3) 0.69 266 (61.9) 164 (38.1) 0.77
   Hebephrenic subtype 233 99 (42.5) 106 (45.5) 28 (12.0) 0.63 134 (57.5) 0.41 304 (65.2) 162 (34.8) 0.33
rs2275199 (N1207N) Exon 37 C/C (%) C/T (%) T/T (%) C/T+T/T (%) C (%) T (%)
Control 492 203 (41.3) 229 (46.5) 60 (12.2) 289 (58.7) 635 (64.5) 349 (35.5)
Schizophrenia 480 198 (41.3) 217 (45.2) 65 (13.5) 0.80 282 (58.7) 1.00 613 (63.9) 347 (36.1) 0.75
   Paranoid subtype 217 78 (35.9) 105 (48.4) 34 (15.7) 0.27 139 (64.1) 0.18 261 (60.1) 173 (39.9) 0.11
   Hebephrenic subtype 236 107 (45.3) 101 (42.8) 28 (11.9) 0.56 129 (54.7) 0.30 315 (66.7) 157 (33.3) 0.40
rs868188 (S1456G) Exon 39 A/A (%) A/G (%) G/G (%) A/G+G/G (%) A (%) G (%)
Control 496 168 (33.9) 223 (44.9) 105 (21.2) 328 (66.1) 559 (56.4) 433 (43.6)
Schizophrenia 480 174 (36.3) 208 (43.3) 98 (20.4) 0.73 306 (63.7) 0.44 556 (57.9) 404 (42.1) 0.48
   Paranoid subtype 216 86 (39.8) 100 (46.3) 30 (13.9) 0.056 130 (60.2) 0.13 272 (62.9) 160 (37.1) 0.020
   Hebephrenic subtype 236 78 (33.1) 98 (41.5) 60 (25.4) 0.41 148 (66.9) 0.83 254 (53.8) 218 (46.2) 0.36
rs945508 (R1467H) Exon 39 G/G (%) G/A (%) A/A (%) G/A+A/A (%) G (%) A (%)
Control 488 363 (74.4) 109 (22.3) 16 (3.3) 125 (25.6) 835 (85.6) 141 (14.4)
Schizophrenia 484 348 (71.9) 115 (23.8) 21 (4.3) 0.56 136 (28.1) 0.38 811 (83.8) 157 (16.2) 0.27
   Paranoid subtype 219 147 (67.1) 63 (28.8) 9 (4.1) 0.13 72 (32.9) 0.046 357 (81.5) 81 (18.5) 0.053
   Hebephrenic subtype 238 180 (75.6) 46 (19.3) 12 (5.1) 0.36 58 (24.4) 0.72 406 (85.3) 70 (14.7) 0.89
Allele
Table 2.
Pairwise linkage disequilibrium between eight single nucleotide polymorphisms of ARHGEF11 .
rs822585 rs6427340 rs6427339 rs1006168 rs12136088 rs2275199 rs868188 rs945508
rs822585 0.92 0.85 0.13 0.13 0.069 0.057 0.56
rs6427340 0.98 0.90 0.14 0.14 0.077 0.055 0.61
rs6427339 0.93 0.97 0.12 0.13 0.065 0.057 0.56
rs1006168 0.89 0.97 0.86 0.97 0.78 0.36 0.08
rs12136088 0.91 0.98 0.90 0.98 0.79 0.36 0.081
rs2275199 0.67 0.72 0.65 0.90 0.91 0.39 0.071
rs868188 0.53 0.53 0.52 0.91 0.91 0.96 0.12
rs945508 0.92 0.93 0.92 0.86 0.87 0.83 0.97
Lower left and upper right diagonals show D'  and r 2  values, respectively. D'  values >0.8 or r 2  values >0.8 are shown in bold.
We define significant LD if D' and  r2 are greater than 0.8.
Rs822585, rs6427340, and rs6427339 constitute one block (block 1), and  rs1006168 and rs12136088 constitute another block (block 2).  

Table 3.
Estimated haplotype frequencies and association significance for ARHGEF11 .
Haplotype
Schizophrenia Control Schizophrenia Global Individual
Block1
 rs822585-rs6427340 A-C 0.80 0.77 0.27 0.13
T-T 0.19 0.21 0.25
T-C 0.007 0.01 0.2
 rs6427340-rs6427339 C-T 0.80 0.76 0.00047 0.071
T-C 0.19 0.21 0.55
C-C 0.004 0.02 0.0010
 rs822585-rs6427340-rs6427339 A-C-T 0.79 0.75 0.0032 0.031
T-T-C 0.19 0.21 0.35
A-C-C 0.004 0.02 0.0018
T-C-T 0.007 0.01 0.21
Block2
 rs1006168-rs12136088 T-T 0.62 0.63 0.16 0.75
G-G 0.37 0.36 0.63
Haplotype
Paranoid subtype Control Paranoid subtype Global Individual
Block 1
 rs822585-rs6427340 A-C 0.80 0.75 0.077 0.043
T-T 0.19 0.24 0.025
 rs6427340-rs6427339 C-T 0.80 0.74 0.0018 0.016
T-C 0.19 0.24 0.080
C-C 0.004 0.01 0.063
 rs822585-rs6427340-rs6427339 A-C-T 0.79 0.74 0.0077 0.019
T-T-C 0.19 0.24 0.049
A-C-C 0.004 0.01 0.064
Block 2
 rs1006168-rs12136088 T-T 0.62 0.61 0.69 0.74
G-G 0.37 0.38 0.67
Haplotype
Hebephrenic subtype Control Hebephrenic subtype Global Individual
Block 1
 rs822585-rs6427340 A-C 0.80 0.78 0.17 0.50
T-T 0.19 0.19 0.94
T-C 0.007 0.02 0.051
 rs6427340-rs6427339 C-T 0.80 0.77 0.000070 0.26
T-C 0.19 0.19 0.78
C-C 0.004 0.03 0.000050
 rs822585-rs6427340-rs6427339 A-C-T 0.79 0.76 0.00025 0.11
T-T-C 0.19 0.19 0.89
A-C-C 0.004 0.03 0.000083
T-C-T 0.007 0.02 0.050
Block 2
 rs1006168-rs12136088 T-T 0.62 0.64 0.073 0.50
G-G 0.37 0.34 0.32
G-T 0.001 0.01 0.0077
Rs822585, rs6427340, and rs6427339 constitute block 1. Rs1006168 and rs12136088 constitute block 2.
Global permutation P  values and individual permutation P  values are indicated.  Significant  P  values are in bold.
Statistical significance was P  <0.05.  Comparisons among schizophrenia subtypes and controls reveal P  < 0.05/3=0.016.
We limited haplotypes to those having frequencies of at least 1% either patients or controls.
Haplotype frequency Permutation P  value
Haplotype frequency Permutation P  value
Haplotype frequency  Permutation P  value
Fig. 1.  
Schematic diagram of the ARHGEF11 gene with introns and exons drawn to scale.  The positions 
of the eight single nucleotide polymorphisms examined in this study are indicated. 
 
